Pages with the most revisions

Jump to navigation Jump to search

Showing below up to 500 results in range #21 to #520.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Quotes from Publications on the System of Radiological Protection‏‎ (13 revisions)
  2. Equivalent dose‏‎ (11 revisions)
  3. Absorbed, Equivalent, and Effective Dose‏‎ (10 revisions)
  4. Air-kerma rate constant‏‎ (9 revisions)
  5. Fundamental Principles of Radiological Protection‏‎ (9 revisions)
  6. Absorbed dose‏‎ (9 revisions)
  7. Objectives of Radiological Protection‏‎ (9 revisions)
  8. Organ/tissue absorbed dose‏‎ (8 revisions)
  9. Beneficence‏‎ (8 revisions)
  10. Prudence‏‎ (8 revisions)
  11. Effects of Exposure‏‎ (8 revisions)
  12. Collective effective dose‏‎ (7 revisions)
  13. ICRPædia Guides‏‎ (6 revisions)
  14. Exposure Categories and Situations‏‎ (6 revisions)
  15. Justice‏‎ (6 revisions)
  16. Alimentary tract‏‎ (6 revisions)
  17. Linear energy transfer‏‎ (6 revisions)
  18. Accelerated fractionation‏‎ (6 revisions)
  19. Investigation level‏‎ (6 revisions)
  20. Principle of optimisation‏‎ (5 revisions)
  21. Air-kerma, entrance surface‏‎ (5 revisions)
  22. ICRPædia Guide to the System of Radiological Protection‏‎ (5 revisions)
  23. Dose coefficient‏‎ (5 revisions)
  24. Justification‏‎ (5 revisions)
  25. Protection quantities‏‎ (5 revisions)
  26. Kerma‏‎ (5 revisions)
  27. Types of materials‏‎ (5 revisions)
  28. Radiation weighting factor‏‎ (5 revisions)
  29. Absorbed fraction‏‎ (5 revisions)
  30. Sources of Radiation Exposure‏‎ (5 revisions)
  31. Quality factor‏‎ (5 revisions)
  32. Diagnostic reference level‏‎ (4 revisions)
  33. S coefficient (radiation weighted)‏‎ (4 revisions)
  34. Non-maleficence‏‎ (4 revisions)
  35. Air-kerma, product‏‎ (4 revisions)
  36. Mass median diameter‏‎ (4 revisions)
  37. Fractionation sensitivity‏‎ (4 revisions)
  38. Programmed cell death‏‎ (4 revisions)
  39. Math‏‎ (4 revisions)
  40. Air kerma at the patient entrance reference point‏‎ (4 revisions)
  41. High linear energy transfer radiation‏‎ (4 revisions)
  42. Bioassay‏‎ (4 revisions)
  43. Calculating Radon Doses‏‎ (4 revisions)
  44. Computed tomography dose index‏‎ (4 revisions)
  45. Direct bioassay‏‎ (4 revisions - redirect page)
  46. Protective action‏‎ (4 revisions)
  47. Reference Animal and Plant‏‎ (4 revisions)
  48. Kp index‏‎ (4 revisions)
  49. Alpha decay‏‎ (4 revisions)
  50. Effective charge number‏‎ (4 revisions)
  51. Source-related assessment‏‎ (4 revisions)
  52. Reference bioassay function‏‎ (4 revisions)
  53. Risk‏‎ (4 revisions)
  54. Senescence‏‎ (4 revisions)
  55. Averted dose‏‎ (4 revisions)
  56. Effective half-life‏‎ (4 revisions)
  57. Optimisation‏‎ (4 revisions)
  58. ICRP‏‎ (4 revisions)
  59. Sievert‏‎ (4 revisions)
  60. Forbiddenness‏‎ (4 revisions)
  61. Aerodynamic diameter‏‎ (4 revisions)
  62. Dose per content function‏‎ (3 revisions)
  63. Iso-effect plots‏‎ (3 revisions)
  64. Lifetime risk estimates‏‎ (3 revisions)
  65. Equity‏‎ (3 revisions)
  66. Virtue ethics‏‎ (3 revisions)
  67. Graded approach‏‎ (3 revisions)
  68. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  69. Isomers‏‎ (3 revisions)
  70. Fractionation‏‎ (3 revisions)
  71. Voxel phantom‏‎ (3 revisions)
  72. Organ dose equivalent‏‎ (3 revisions)
  73. Active (red) bone marrow‏‎ (3 revisions)
  74. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  75. Coster-Kronig transition‏‎ (3 revisions)
  76. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  77. Recovery‏‎ (3 revisions)
  78. Spread-out Bragg peak‏‎ (3 revisions)
  79. Emergency preparedness‏‎ (3 revisions)
  80. Gray‏‎ (3 revisions)
  81. Auger transition‏‎ (3 revisions)
  82. Bystander effect‏‎ (3 revisions)
  83. Emergency procedures‏‎ (3 revisions)
  84. Absolute risk‏‎ (3 revisions)
  85. Wisdom‏‎ (3 revisions)
  86. Complex tissues‏‎ (3 revisions)
  87. Derived air concentration‏‎ (3 revisions)
  88. Dignity‏‎ (3 revisions)
  89. Employer‏‎ (3 revisions)
  90. Target region‏‎ (3 revisions)
  91. Activity median thermodynamic diameter‏‎ (3 revisions)
  92. Growth fraction‏‎ (3 revisions)
  93. Potential exposure‏‎ (3 revisions)
  94. ICRP Publication 103‏‎ (3 revisions)
  95. Excretion rate (instantaneous)‏‎ (3 revisions)
  96. Extrathoracic airways‏‎ (3 revisions)
  97. Galactic cosmic radiation‏‎ (3 revisions)
  98. Growth hormone (somatotropin)‏‎ (3 revisions)
  99. DNA damage signalling‏‎ (3 revisions)
  100. Rigidity threshold‏‎ (3 revisions)
  101. Low Earth orbit‏‎ (3 revisions)
  102. Fairness‏‎ (3 revisions)
  103. Absorption‏‎ (3 revisions)
  104. Gamma ray‏‎ (3 revisions)
  105. X ray‏‎ (3 revisions)
  106. Biomedical research volunteer‏‎ (3 revisions)
  107. Cardiomyopathy‏‎ (3 revisions)
  108. Dose equivalent‏‎ (3 revisions)
  109. Field-size effect (Volume effect)‏‎ (3 revisions)
  110. Unsealed source‏‎ (3 revisions)
  111. Gastrointestinal syndrome‏‎ (3 revisions)
  112. Xerostomia‏‎ (3 revisions)
  113. Guide to the System of Radiological Protection‏‎ (3 revisions)
  114. Autonomy‏‎ (3 revisions)
  115. Public exposure‏‎ (3 revisions)
  116. Dose limit‏‎ (3 revisions)
  117. Interphase death‏‎ (3 revisions)
  118. Test‏‎ (3 revisions)
  119. Flexible tissues‏‎ (3 revisions)
  120. Constancy test‏‎ (3 revisions)
  121. Dose‏‎ (3 revisions)
  122. Dose limits‏‎ (3 revisions)
  123. Fluence‏‎ (3 revisions)
  124. Uptake‏‎ (3 revisions)
  125. Annual dose‏‎ (3 revisions)
  126. DS02‏‎ (3 revisions)
  127. Fluoroscopically guided interventions‏‎ (3 revisions)
  128. Utilitarian ethics‏‎ (3 revisions)
  129. Operational quantity‏‎ (3 revisions)
  130. Half-life, physical‏‎ (3 revisions)
  131. Cell death‏‎ (3 revisions)
  132. Contamination‏‎ (3 revisions)
  133. Dose of record (E)‏‎ (3 revisions)
  134. Accountability‏‎ (3 revisions)
  135. Value judgement‏‎ (3 revisions)
  136. Annual limit on intake‏‎ (3 revisions)
  137. Personal dose equivalent‏‎ (3 revisions)
  138. Principle of justification‏‎ (3 revisions)
  139. Radiofrequency ablation‏‎ (3 revisions)
  140. Exponential survival curve‏‎ (3 revisions)
  141. Valvular heart disease‏‎ (3 revisions)
  142. Health Surveillance‏‎ (2 revisions)
  143. Basal cell‏‎ (2 revisions)
  144. Branching fraction‏‎ (2 revisions)
  145. Chronic exposure‏‎ (2 revisions)
  146. Radiographer‏‎ (2 revisions)
  147. Colony‏‎ (2 revisions)
  148. Cosmic Radiation in Aviation‏‎ (2 revisions)
  149. Decommissioning‏‎ (2 revisions)
  150. Representative organism (non-human biota)‏‎ (2 revisions)
  151. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  152. Dose-threshold‏‎ (2 revisions)
  153. Threshold dose for tissue reactions‏‎ (2 revisions)
  154. Magnetosphere‏‎ (2 revisions)
  155. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  156. Action Level‏‎ (2 revisions)
  157. Heliosphere‏‎ (2 revisions)
  158. Pharynx‏‎ (2 revisions)
  159. Class SR-0 gases‏‎ (2 revisions)
  160. Decontamination‏‎ (2 revisions)
  161. Representative person‏‎ (2 revisions)
  162. Diastasis‏‎ (2 revisions)
  163. Safety‏‎ (2 revisions)
  164. Dose per unit intake coefficient‏‎ (2 revisions)
  165. Specific effective energy‏‎ (2 revisions)
  166. Emergency‏‎ (2 revisions)
  167. Limitation of dose‏‎ (2 revisions)
  168. Exposure, external or internal‏‎ (2 revisions)
  169. Transmission detection system‏‎ (2 revisions)
  170. Multistage tumorigenesis‏‎ (2 revisions)
  171. Non-sphericity parameter‏‎ (2 revisions)
  172. Graft vs host disease‏‎ (2 revisions)
  173. Air-kerma, incident‏‎ (2 revisions)
  174. Procedural values‏‎ (2 revisions)
  175. Broad beam therapy irradiation technique‏‎ (2 revisions)
  176. Class SR-1 gases‏‎ (2 revisions)
  177. Committed effective dose‏‎ (2 revisions)
  178. Cost-benefit analysis‏‎ (2 revisions)
  179. Decontamination factor‏‎ (2 revisions)
  180. Reproductive integrity‏‎ (2 revisions)
  181. Safety case‏‎ (2 revisions)
  182. Slow repair‏‎ (2 revisions)
  183. Dose rate‏‎ (2 revisions)
  184. Isotropic geometry‏‎ (2 revisions)
  185. Emergency exposure situation‏‎ (2 revisions)
  186. Lineal energy‏‎ (2 revisions)
  187. Erythropoietin‏‎ (2 revisions)
  188. Thyroid blocking‏‎ (2 revisions)
  189. Exposure (in the context of inhalation)‏‎ (2 revisions)
  190. Transparency‏‎ (2 revisions)
  191. Fractionation and dose delivery patterns‏‎ (2 revisions)
  192. Waste disposal‏‎ (2 revisions)
  193. Non-targeted effects‏‎ (2 revisions)
  194. Orphan source‏‎ (2 revisions)
  195. Hierarchical tissues‏‎ (2 revisions)
  196. Area monitoring‏‎ (2 revisions)
  197. Planned exposure situation‏‎ (2 revisions)
  198. Benthic‏‎ (2 revisions)
  199. Progenitor cell‏‎ (2 revisions)
  200. Bronchial region‏‎ (2 revisions)
  201. Radiation belt‏‎ (2 revisions - redirect page)
  202. Class SR-2 gases‏‎ (2 revisions)
  203. Committed equivalent dose‏‎ (2 revisions)
  204. Reasonableness‏‎ (2 revisions)
  205. Residual dose‏‎ (2 revisions)
  206. Dichotomous‏‎ (2 revisions)
  207. Safety culture‏‎ (2 revisions)
  208. Solar cosmic radiation‏‎ (2 revisions)
  209. Inhalability‏‎ (2 revisions)
  210. Dose rate effectiveness factor‏‎ (2 revisions)
  211. Spontaneous fission‏‎ (2 revisions)
  212. Itinerant (radiation) worker‏‎ (2 revisions)
  213. Emergency plan‏‎ (2 revisions)
  214. Linear-non-threshold model‏‎ (2 revisions)
  215. Ethics‏‎ (2 revisions)
  216. ALARA‏‎ (2 revisions)
  217. Trapped particles‏‎ (2 revisions)
  218. High level waste‏‎ (2 revisions)
  219. Platelet-derived growth factor‏‎ (2 revisions)
  220. Radiation modifier‏‎ (2 revisions)
  221. Clearance‏‎ (2 revisions)
  222. Radiological protection principles‏‎ (2 revisions)
  223. Deontological Ethics‏‎ (2 revisions)
  224. Respiratory protection‏‎ (2 revisions)
  225. Differentiation‏‎ (2 revisions)
  226. Scintigraphy‏‎ (2 revisions)
  227. Solar cycle‏‎ (2 revisions)
  228. Inner bremsstrahlung‏‎ (2 revisions)
  229. Systemic model‏‎ (2 revisions)
  230. Linear-quadratic dose response model‏‎ (2 revisions)
  231. Time factor‏‎ (2 revisions)
  232. Myocardial perfusion‏‎ (2 revisions)
  233. Activity‏‎ (2 revisions)
  234. What is Radon?‏‎ (2 revisions)
  235. Oversight‏‎ (2 revisions)
  236. Beta-minus decay‏‎ (2 revisions)
  237. Projected dose‏‎ (2 revisions)
  238. Clearance level‏‎ (2 revisions)
  239. Radionuclides of natural origin‏‎ (2 revisions)
  240. Recovery (cellular or tissue)‏‎ (2 revisions)
  241. Retrievability‏‎ (2 revisions)
  242. Immune system‏‎ (2 revisions)
  243. Dose constraint‏‎ (2 revisions)
  244. Institutional control‏‎ (2 revisions)
  245. Early normal tissue responses‏‎ (2 revisions)
  246. Stakeholder‏‎ (2 revisions)
  247. Tachycardia‏‎ (2 revisions)
  248. Tissue equivalent material‏‎ (2 revisions)
  249. Myocardial stress test‏‎ (2 revisions)
  250. Beta-plus decay‏‎ (2 revisions)
  251. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  252. Radiation safety officer‏‎ (2 revisions)
  253. Radioresponsiveness‏‎ (2 revisions)
  254. Recovery responder‏‎ (2 revisions)
  255. Cumulative dose‏‎ (2 revisions)
  256. Reversibility‏‎ (2 revisions)
  257. In vivo radiobioassay‏‎ (2 revisions)
  258. Dose conversion coefficient‏‎ (2 revisions)
  259. Solar particle event‏‎ (2 revisions)
  260. Edema‏‎ (2 revisions)
  261. Excess relative risk‏‎ (2 revisions)
  262. Exposure situation‏‎ (2 revisions)
  263. Worker‏‎ (2 revisions)
  264. Nuclear track detectors‏‎ (2 revisions)
  265. Growth factor‏‎ (2 revisions)
  266. Alimentary tract transfer factor‏‎ (2 revisions)
  267. Particle radiance‏‎ (2 revisions)
  268. Hormones‏‎ (2 revisions)
  269. Authorization‏‎ (2 revisions)
  270. Protection strategy‏‎ (2 revisions)
  271. Radiation source‏‎ (2 revisions)
  272. Clonogenic cells‏‎ (2 revisions)
  273. Radiosensitiser‏‎ (2 revisions)
  274. Curie‏‎ (2 revisions)
  275. Rehabilitation of living conditions‏‎ (2 revisions)
  276. Right to know‏‎ (2 revisions)
  277. Incidence‏‎ (2 revisions)
  278. Solar wind‏‎ (2 revisions)
  279. Effect Dose 50‏‎ (2 revisions)
  280. Endogeneous excretion‏‎ (2 revisions)
  281. Target tissue‏‎ (2 revisions)
  282. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  283. Exposure to Radon at Home‏‎ (2 revisions)
  284. GATA binding protein 2‏‎ (2 revisions)
  285. Working level‏‎ (2 revisions)
  286. OLINDA/EXM‏‎ (2 revisions)
  287. Hounsfield unit‏‎ (2 revisions)
  288. Authorized limit‏‎ (2 revisions)
  289. Cardiac arrhythmias‏‎ (2 revisions)
  290. Clonogenic survival‏‎ (2 revisions)
  291. Radiosensitivity, cellular‏‎ (2 revisions)
  292. Cytokines‏‎ (2 revisions)
  293. Rigidity‏‎ (2 revisions)
  294. Security‏‎ (2 revisions)
  295. Incident‏‎ (2 revisions)
  296. Intermediate level waste‏‎ (2 revisions)
  297. Stenosis‏‎ (2 revisions)
  298. Local DRL‏‎ (2 revisions)
  299. Tolerability‏‎ (2 revisions)
  300. Medical exposure‏‎ (2 revisions)
  301. Naturally occurring radioactive material‏‎ (2 revisions)
  302. Acute radiation syndrome‏‎ (2 revisions)
  303. Working level month‏‎ (2 revisions)
  304. Alveolar-interstitial region‏‎ (2 revisions)
  305. Patient entrance reference point‏‎ (2 revisions)
  306. Autoimmune disease‏‎ (2 revisions)
  307. Potential recoverability correction factor‏‎ (2 revisions)
  308. Protective action guide‏‎ (2 revisions)
  309. ICRP Publication 118‏‎ (2 revisions)
  310. Cardiac valve diseases‏‎ (2 revisions)
  311. Radiation worker‏‎ (2 revisions)
  312. Disposal‏‎ (2 revisions)
  313. Inclusiveness‏‎ (2 revisions)
  314. Dose criteria‏‎ (2 revisions)
  315. Source-related‏‎ (2 revisions)
  316. Internal conversion electron‏‎ (2 revisions)
  317. LD 50/30‏‎ (2 revisions)
  318. Environmental exposure‏‎ (2 revisions)
  319. Telangiectasia‏‎ (2 revisions)
  320. Exempt waste‏‎ (2 revisions)
  321. Member of the public‏‎ (2 revisions)
  322. Unattached fraction‏‎ (2 revisions)
  323. Necrosis‏‎ (2 revisions)
  324. Adaptive response‏‎ (2 revisions)
  325. Peak skin dose‏‎ (2 revisions)
  326. Radioactive dispersion device‏‎ (2 revisions)
  327. Co-expertise‏‎ (2 revisions)
  328. Radon: Units of Measure‏‎ (2 revisions)
  329. Connective tissue‏‎ (2 revisions)
  330. Reference air kerma‏‎ (2 revisions)
  331. DRL process‏‎ (2 revisions)
  332. Self-help protection‏‎ (2 revisions)
  333. Individual-related‏‎ (2 revisions)
  334. Storage‏‎ (2 revisions)
  335. Environmental radiation protection‏‎ (2 revisions)
  336. Exemption level‏‎ (2 revisions)
  337. Track structure‏‎ (2 revisions)
  338. Mendelian diseases‏‎ (2 revisions)
  339. Neurological syndrome‏‎ (2 revisions)
  340. Occupational exposure‏‎ (2 revisions)
  341. Angiogenesis‏‎ (2 revisions)
  342. Pelagic‏‎ (2 revisions)
  343. Hyperbaric oxygen‏‎ (2 revisions)
  344. Practical radiological protection culture‏‎ (2 revisions)
  345. Bioturbation‏‎ (2 revisions)
  346. Cardioverter-defibrillator‏‎ (2 revisions)
  347. Radioactive source‏‎ (2 revisions)
  348. Consequential late effects‏‎ (2 revisions)
  349. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  350. Individual decontamination‏‎ (2 revisions)
  351. Effective dose equivalent‏‎ (2 revisions)
  352. Subcutaneous tissue‏‎ (2 revisions)
  353. Low dose rate‏‎ (2 revisions)
  354. Existing exposure situation‏‎ (2 revisions)
  355. Transfer compartment‏‎ (2 revisions)
  356. Mitigation‏‎ (2 revisions)
  357. Upper reference levels‏‎ (2 revisions)
  358. Neurovascular syndrome‏‎ (2 revisions)
  359. Gastroschisis‏‎ (2 revisions)
  360. Habitual mouth breather‏‎ (2 revisions)
  361. Annihilation photons‏‎ (2 revisions)
  362. Hyperfractionation‏‎ (2 revisions)
  363. Bone marrow‏‎ (2 revisions)
  364. Qualified expert‏‎ (2 revisions)
  365. Radioactive substance‏‎ (2 revisions)
  366. Cohort study‏‎ (2 revisions)
  367. Reference biokinetic model‏‎ (2 revisions)
  368. DRL value‏‎ (2 revisions)
  369. Relocation‏‎ (2 revisions)
  370. Risk coefficient‏‎ (2 revisions)
  371. Individual monitoring‏‎ (2 revisions)
  372. Source term‏‎ (2 revisions)
  373. Latent time/period or latency interval‏‎ (2 revisions)
  374. Epithelium‏‎ (2 revisions)
  375. Low level waste‏‎ (2 revisions)
  376. Acceptance test‏‎ (2 revisions)
  377. Gastrulation‏‎ (2 revisions)
  378. Habitual nose breather‏‎ (2 revisions)
  379. Percutaneous coronary intervention‏‎ (2 revisions)
  380. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  381. Background dose (rate)‏‎ (2 revisions)
  382. Prevailing circumstances‏‎ (2 revisions)
  383. Radon Recommendations for Authorities‏‎ (2 revisions)
  384. Containment‏‎ (2 revisions)
  385. Reference individual‏‎ (2 revisions)
  386. Remedial action‏‎ (2 revisions)
  387. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  388. Dose-length product‏‎ (2 revisions)
  389. Intervention Level‏‎ (2 revisions)
  390. Substantial radiation dose level‏‎ (2 revisions)
  391. Equieffective dose‏‎ (2 revisions)
  392. Expanded and aligned radiation field‏‎ (2 revisions)
  393. Transfer rate‏‎ (2 revisions)
  394. Multi-detector computed tomography‏‎ (2 revisions)
  395. Adventitious‏‎ (2 revisions)
  396. Pericarditis‏‎ (2 revisions)
  397. Hypoplasia‏‎ (2 revisions)
  398. Backscatter detection system‏‎ (2 revisions)
  399. Principle of application of dose limits‏‎ (2 revisions)
  400. Bradycardia‏‎ (2 revisions)
  401. Radioactivity‏‎ (2 revisions)
  402. Radon Recommendations for Workplaces‏‎ (2 revisions)
  403. Reference level‏‎ (2 revisions)
  404. Remediation‏‎ (2 revisions)
  405. Detriment‏‎ (2 revisions)
  406. Risk of Exposure to Radon‏‎ (2 revisions)
  407. Dose-rate effect‏‎ (2 revisions)
  408. South Atlantic anomaly‏‎ (2 revisions)
  409. Interventional procedure‏‎ (2 revisions)
  410. Electron-capture decay‏‎ (2 revisions)
  411. Lymphatic system‏‎ (2 revisions)
  412. Transforming growth factor‏‎ (2 revisions)
  413. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  414. Hazard‏‎ (2 revisions)
  415. Bragg peak‏‎ (2 revisions)
  416. Coronary heart disease‏‎ (2 revisions)
  417. Decay constant‏‎ (2 revisions)
  418. Repopulation‏‎ (2 revisions)
  419. Routine monitoring‏‎ (2 revisions)
  420. ICRPædia Guide to Radon‏‎ (2 revisions)
  421. Dose of record Hp (10)‏‎ (2 revisions)
  422. Special (non-routine) monitoring‏‎ (2 revisions)
  423. Electrophysiology‏‎ (2 revisions)
  424. Lifetime risk‏‎ (2 revisions)
  425. Macrophage colony stimulating factor‏‎ (2 revisions)
  426. Multiplicative risk projection model‏‎ (2 revisions)
  427. Accreditation‏‎ (2 revisions)
  428. Genomic integrity‏‎ (2 revisions)
  429. Apoptosis‏‎ (1 revision)
  430. Phantom‏‎ (1 revision)
  431. ICRP Publication 11‏‎ (1 revision)
  432. ICRP Publication 124‏‎ (1 revision)
  433. ICRP Publication 139‏‎ (1 revision)
  434. Ras‏‎ (1 revision)
  435. ICRP Publication 153‏‎ (1 revision)
  436. Reference phantom‏‎ (1 revision)
  437. ICRP Publication 28‏‎ (1 revision)
  438. ICRP Publication 90‏‎ (1 revision)
  439. ICRP Publication 34‏‎ (1 revision)
  440. ICRP Publication 49‏‎ (1 revision)
  441. Size-specific dose estimate‏‎ (1 revision)
  442. ICRP Publication 63‏‎ (1 revision)
  443. Specific absorbed fraction‏‎ (1 revision)
  444. ICRP Publication 78‏‎ (1 revision)
  445. Elemental dose‏‎ (1 revision)
  446. Surface contamination‏‎ (1 revision)
  447. Exposed individuals‏‎ (1 revision)
  448. 1954 Recommendations‏‎ (1 revision)
  449. Translocation‏‎ (1 revision)
  450. Multistage carcinogenesis model‏‎ (1 revision)
  451. Organ at risk‏‎ (1 revision)
  452. ICRP Publication 1‏‎ (1 revision)
  453. Baseline disease rates‏‎ (1 revision)
  454. Principles of protection‏‎ (1 revision)
  455. ICRP Publication 110‏‎ (1 revision)
  456. Breakpoint cluster region/abelson‏‎ (1 revision)
  457. Radiation-induced second cancer‏‎ (1 revision)
  458. ICRP Publication 125‏‎ (1 revision)
  459. ICRP Publication 14‏‎ (1 revision)
  460. Commissioning‏‎ (1 revision)
  461. Rb‏‎ (1 revision)
  462. ICRP Publication 154‏‎ (1 revision)
  463. Cosmic radiation‏‎ (1 revision)
  464. Reference value‏‎ (1 revision)
  465. ICRP Publication 29‏‎ (1 revision)
  466. ICRP Publication 91‏‎ (1 revision)
  467. ICRP Publication 35‏‎ (1 revision)
  468. ICRP Publication 5‏‎ (1 revision)
  469. Dose-threshold hypothesis‏‎ (1 revision)
  470. Slice‏‎ (1 revision)
  471. ICRP Publication 64‏‎ (1 revision)
  472. ICRP Publication 79‏‎ (1 revision)
  473. Threshold level‏‎ (1 revision)
  474. 1956 Recommendations‏‎ (1 revision)
  475. Activation‏‎ (1 revision)
  476. Hereditary effect‏‎ (1 revision)
  477. Pilomatricoma‏‎ (1 revision)
  478. ICRP Publication 10‏‎ (1 revision)
  479. ICRP Publication 111‏‎ (1 revision)
  480. Radiation-induced secondary malignancy‏‎ (1 revision)
  481. ICRP Publication 126‏‎ (1 revision)
  482. Radiological attack‏‎ (1 revision)
  483. ICRP Publication 140‏‎ (1 revision)
  484. Reactive oxygen species‏‎ (1 revision)
  485. ICRP Publication 155‏‎ (1 revision)
  486. Reference worker‏‎ (1 revision)
  487. ICRP Publication 3‏‎ (1 revision)
  488. ICRP Publication 92‏‎ (1 revision)
  489. ICRP Publication 36‏‎ (1 revision)
  490. Dicentric chromosome‏‎ (1 revision)
  491. ICRP Publication 50‏‎ (1 revision)
  492. Dose and dose-rate effectiveness factor‏‎ (1 revision)
  493. Informed consent‏‎ (1 revision)
  494. ICRP Publication 65‏‎ (1 revision)
  495. Spongiosa‏‎ (1 revision)
  496. ICRP Publication 8‏‎ (1 revision)
  497. Marrow cellularity‏‎ (1 revision)
  498. 1959 Decisions‏‎ (1 revision)
  499. Multitarget equation‏‎ (1 revision)
  500. ICRP Publication 100‏‎ (1 revision)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:MostRevisions"